leadf
logo-loader
viewTissue Regenix Group PLC

Full interview: Tissue Regenix to boost production capacity as its sees strong global demand for its products

Tissue Regenix Group PLC's (LON:TRX) Gareth Jones tells Proactive London's Andrew Scott they're focused on initiatives to increase capacity and alleviate supply constraints as they continue to see strong demand for its products.

Sales rose £500,000 to £6.1mln during the six months ended June 30, boosted by revenues from its DermaPure skin repair product, which grew by 33% to £2mln.

Quick facts: Tissue Regenix Group PLC

Price: 0.3391 GBX

AIM:TRX
Market: AIM
Market Cap: £23.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read